

Special Issue

Integrative and Multi-Modality Therapy in the Next Generation of Hepatocellular Carcinoma Management

Message from the Guest Editors

In the last few years, there has been a seismic shift in the available therapies for hepatocellular carcinoma (HCC). Multidisciplinary care encompasses surgical, interventional radiology, transplant, radiation and systemic therapy options, including the potential use of systemic therapies for HCC in the neo-adjuvant, adjuvant and advanced settings. This Special Issue is looking for original manuscripts and reviews to explore all areas of treatment, including the following:

- Screening approaches;
- Cirrhosis management in the setting of HCC;
- Molecular classification, prognostic, and predictive biomarkers;
- New approaches in both interventional radiology, radiation, and surgical procedures;
- Approaches of neo-adjuvant strategies and adjuvant therapies;
- Multi-modality therapy in the advanced and metastatic setting;
- Therapy sequencing in early and advanced disease;
- Developments in immunotherapy and immunotherapy-based combinations.

We look forward to receiving your contributions.

Guest Editors

Dr. Brandon M. Meyers

Dr. Howard Lim

Dr. Anand Swaminath

Dr. Pablo Emilio Serrano

Deadline for manuscript submissions

closed (31 October 2024)



**Current
Oncology**

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



mdpi.com/si/193664

Current Oncology
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
currentoncology@mdpi.com

[mdpi.com/journal/
currentoncology](https://mdpi.com/journal/currentoncology)





Current Oncology

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 4.9
Indexed in PubMed



[mdpi.com/journal/
currenocol](https://mdpi.com/journal/currenocol)



About the Journal

Message from the Editor-in-Chief

I am honored and enthusiastic to serve as Editor-in-Chief of *Current Oncology*. Since its establishment in 1994, *Current Oncology* has been playing an important role in the advancement of cancer care by disseminating new knowledge in the cancer care continuum. *Current Oncology* is affiliated with several key cancer societies and provides a global platform to share scientific progress in oncology. We strive for high standards and work together to maintain a rigorous and unbiased peer review process to publish high-quality articles. We have an outstanding editorial team which is committed to the success of *Current Oncology*.

Editor-in-Chief

Prof. Dr. Shahid Ahmed

1. College of Medicine, University of Saskatchewan, Saskatoon, SK S7N5E5, Canada

2. Saskatchewan Cancer Agency, Saskatoon Cancer Center, Saskatoon, SK S7N5H5, Canada

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, and other databases.

Journal Rank:

JCR - Q2 (Oncology)